BS_GWCRMKE6
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- overall_survival_months
- 84.13272010512483
- age_years
- 15.153
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.570
- INTERFERON_GAMMA_RESPONSE+0.545
- IL6_JAK_STAT3_SIGNALING+0.541
- ALLOGRAFT_REJECTION+0.520
- CHOLESTEROL_HOMEOSTASIS+0.508
- INFLAMMATORY_RESPONSE+0.492
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.471
- BILE_ACID_METABOLISM+0.452
- MYOGENESIS+0.428
- COAGULATION+0.426
Top 10 suppressed
- E2F_TARGETS-0.576
- MYC_TARGETS_V1-0.539
- G2M_CHECKPOINT-0.533
- MYC_TARGETS_V2-0.443
- DNA_REPAIR-0.329
- MITOTIC_SPINDLE-0.252
- WNT_BETA_CATENIN_SIGNALING-0.252
- OXIDATIVE_PHOSPHORYLATION-0.235
- UNFOLDED_PROTEIN_RESPONSE-0.230
- SPERMATOGENESIS-0.075
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_5NWDARXG | pilocytic astrocytoma | — | 0.968 |
| 2 | BS_E4GC9EXR | Ganglioglioma | — | 0.965 |
| 3 | BS_NRPG5K4K | low-grade glioma | — | 0.953 |
| 4 | BS_2ADZNNV4 | pilocytic astrocytoma | — | 0.951 |
| 5 | SRR5088929 | — | — | 0.949 |
| 6 | BS_M4TTKPNR | pilocytic astrocytoma | — | 0.949 |
| 7 | BS_V89HGTET | pilocytic astrocytoma | — | 0.944 |
| 8 | BS_8VAZSJEN | pilocytic astrocytoma | — | 0.939 |
| 9 | BS_769BDPDB | pilocytic astrocytoma | — | 0.939 |
| 10 | BS_HC5M8JTC | low-grade glioma | — | 0.937 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.570 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.545 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.541 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.520 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.508 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.492 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.471 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.452 | Inavolisib | — uncovered |
| MYOGENESIS | 0.428 | Inavolisib | — uncovered |
| COAGULATION | 0.426 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.426 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.424 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.407 | Idelalisib | — uncovered |
| COMPLEMENT | 0.398 | Inavolisib | — uncovered |
| APOPTOSIS | 0.379 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.350 | Inavolisib | — uncovered |
| HYPOXIA | 0.345 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.339 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.333 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.326 | Inavolisib | — uncovered |